Minamino, Hiroto
Katsushima, Masao
Torii, Mie
Hashimoto, Motomu
Fujita, Yoshihito
Ikeda, Kaori
Yamamoto, Wataru
Watanabe, Ryu
Murakami, Kosaku
Murata, Koichi
Nishitani, Kohei
Tanaka, Masao
Ito, Hiromu
Ohmura, Koichiro
Arai, Hidenori
Inagaki, Nobuya
Matsuda, Shuichi
Article History
Received: 23 May 2020
Accepted: 17 February 2021
First Online: 3 March 2021
Competing interests
: M.H., R.W. K.M. (Murata), K.N., and M.T. (Tanaka) belong to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei). KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd. M.H. receives grants and/or speaker fees from Bristol-Meyers, Eisai, Eli Lilly, and Tanabe Mitsubishi. R.W. receives speaker’s fee from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb, and Janssen. K.N. received a research grant from Asahi-Kasei Pharma. H.I. receives a research grant and/or speaker fee from Bristol-Myers, Kyocera, and Asahi-Kasei. K.O. has received research grants and/or speaker’s fee from Abbvie, Actelion, Asahikasei Pharma, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, JB, Mitsubishi Tanabe, Nippon Kayaku, Nippon Shinyaku, Novartis, Sanofi and Takeda. S.M. receives grants and/or speaker fees from Daiichi Sankyo, Asahi-Kasei, Chugai, Ayumi, and Tanabe Mitsubishi. H.M., M.K., M.T. (Torii), Y.F., K.I., W.Y., K.M.(Murakami), H.A., and N.I. declare no conflicts of interest. The sponsors had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript or the decision to submit the manuscript for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.